Results 261 to 270 of about 106,090 (294)
Some of the next articles are maybe not open access.
Angiotensin-Converting Enzyme Inhibitors
2000Angiotensin-converting enzyme (ACE) inhibitors have been available for more than a decade for clinical use to treat hypertension and congestive heart failure (CHI). An intravenous agent, enalaprilat, has been approved by the Food and Drug Administration (FDA) for use in hypertension, and ten oral agents—benazepril, captopril, enalapril, fosinopril ...
William H. Frishman +2 more
openaire +1 more source
Angiotensin Converting Enzyme Inhibitors
1999The synthesis of the first orally active angiotensin converting enzyme (ACE) inhibitor in the 1977, heralded one of the major therapeutic advances of the last decades. Initially designed to be a pathophysiological meaningful tool for the treatment of severe malignant hypertension, ACE inhibitors are now widely accepted as first line approach to the ...
openaire +1 more source
Metal–Organic Framework-Based Enzyme Biocomposites
Chemical Reviews, 2021, Peter Wied, Francesco Carraro
exaly
Bioinspired Framework Catalysts: From Enzyme Immobilization to Biomimetic Catalysis
Chemical Reviews, 2023Kun-Yu Wang, Jiandong Pang, Wei Shi
exaly
Angiotensin-converting enzyme inhibitors
Journal of the American Academy of Dermatology, 1993Anil Abraham, Eugene Farber
openaire +2 more sources
Angiotensin converting enzyme Inhibitors
American Heart Journal, 1989Robert A. Scott, David B. Barnett
+5 more sources
Treatment of renal cell carcinoma: Current status and future directions
Ca-A Cancer Journal for Clinicians, 2017Pedro Coelho Barata, Brian I Rini
exaly
Lung cancer: New biological insights and recent therapeutic advances
Ca-A Cancer Journal for Clinicians, 2011Suresh S Ramalingam, Fadlo R Khuri
exaly